This POSTnote describes some of the new models of Children and Young People Mental Health Services (CYPMHS) and examines the challenges to their effective implementation.
Mental Health Service Models for Young People (558 KB , PDF)
In 2015, the Government committed 5 years of extra funding for Children and Young People’s Mental Health Services (CYPMHS). All areas of England were required to submit plans outlining how they will improve their services by 2020. This POSTnote describes some of the new models of CYPMHS and examines the challenges to their effective implementation.
Acknowledgements
POSTnotes are based on literature reviews and interviews with
a range of stakeholders and are externally peer reviewed.
POST would like to thank interviewees and peer reviewers
for kindly giving up their time during the preparation of this briefing
including:
Polly Ashmore, NHS England
Nigel Atter, British Psychological Society
Andy Bell, Centre for Mental Health
Elaine Bousfield, Xenzone
Dr Marc Bush, YoungMinds
Sinem Cakir, MAC-UK
Emily Frith, Education Policy Institute
Professor Peter Fonagy, UCL, Anna Freud National Centre
for Children and Families.
James Kenrick, Youth Access
Paula Lavis, Children and Young People’s Mental Health Coalition
David Lockwood, NHS England
Emma Louisy, Tavistock and Portman NHS Foundation
Anna Moore, Tavistock and Portman NHS Foundation
Lisa Nolan, Liverpool CCG
Fiona Pienaar, Place2Be
Tom Powell, House of Commons Library
Kathryn Pugh, NHS England
Mental Health Service Models for Young People (558 KB , PDF)
The B.1.617.2 variant was first observed in India and is rapidly spreading in the UK. What is known about effectiveness of vaccines against this variant - and how close to the finish line are the other vaccines already secured by the UK?
Real-world data shows that COVID-19 vaccines deployed in the UK are effective in protecting against SARS-CoV-2 transmission already after a single dose. Are all the other COVID-19 vaccines equally effective? What is the evidence on balancing between vaccinations and lifting restrictions?
The safety of COVID-19 vaccines currently deployed in the UK is closely monitored. This monitoring has shown that the University of Oxford/AstraZeneca vaccine is associated with very rare blood clots. What is known about these very rare adverse events?
